These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32967146)

  • 1. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model.
    Lin CH; Chiu SI; Chen TF; Jang JR; Chiu MJ
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease.
    Chung CC; Chan L; Chen JH; Bamodu OA; Chiu HW; Hong CT
    FASEB J; 2021 Oct; 35(10):e21895. PubMed ID: 34478572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.
    Chiu PY; Yang FC; Chiu MJ; Lin WC; Lu CH; Yang SY
    Sci Rep; 2022 Oct; 12(1):17919. PubMed ID: 36289355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How many biomarkers to discriminate neurodegenerative dementia?
    Sancesario GM; Bernardini S
    Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.
    Ding J; Zhang J; Wang X; Zhang L; Jiang S; Yuan Y; Li J; Zhu L; Zhang K
    J Neural Transm (Vienna); 2017 Mar; 124(3):353-360. PubMed ID: 27878377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson's disease.
    Chojdak-Łukasiewicz J; Małodobra-Mazur M; Zimny A; Noga L; Paradowski B
    Adv Clin Exp Med; 2020 Jan; 29(1):115-121. PubMed ID: 31990459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
    Chiu MJ; Yang SY; Horng HE; Yang CC; Chen TF; Chieh JJ; Chen HH; Chen TC; Ho CS; Chang SF; Liu HC; Hong CY; Yang HC
    ACS Chem Neurosci; 2013 Dec; 4(12):1530-6. PubMed ID: 24090201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative.
    Sanchez E; Wilkinson T; Coughlan G; Mirza S; Baril AA; Ramirez J; Binns MA; Black SE; Borrie M; Dilliott AA; Dixon RA; Dowlatshahi D; Farhan S; Finger E; Fischer CE; Frank A; Freedman M; Goncalves RA; Grimes DA; Hassan A; Hegele RA; Kumar S; Lang AE; Marras C; McLaughlin PM; Orange JB; Pasternak SH; Pollock BG; Rajji TK; Roberts AC; Robinson JF; Rogaeva E; Sahlas DJ; Saposnik G; Strong MJ; Swartz RH; Tang-Wai DF; Tartaglia MC; Troyer AK; Kvartsberg H; Zetterberg H; Munoz DP; ; Masellis M
    Alzheimers Dement; 2024 Mar; 20(3):1753-1770. PubMed ID: 38105605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
    Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
    J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
    Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
    J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.
    Sheinerman KS; Toledo JB; Tsivinsky VG; Irwin D; Grossman M; Weintraub D; Hurtig HI; Chen-Plotkin A; Wolk DA; McCluskey LF; Elman LB; Trojanowski JQ; Umansky SR
    Alzheimers Res Ther; 2017 Nov; 9(1):89. PubMed ID: 29121998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.